Extended Data Table 6 Management of nonhematological and hematological toxicities

From: Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial

  1. CTCAE v5, Common Terminology Criteria for Adverse Events version 5.0; G-CSF, granulocyte colony-stimulating factor. *Refer to Extended Data Table 5 regarding the sequencing of study drug dose adjustments. †When an adverse event of anemia occurred, common causes of treatable anemia (such as iron, vitamin B12, or folate deficiency, and hypothyroidism) were investigated and treated accordingly. Blood transfusions were acceptable at the investigator’s discretion and according to local guidelines. ‡When adverse events of thrombocytopenia occurred, appropriate supportive care was provided according to local guidelines. If indicated, platelet transfusion therapy was performed according to the investigator’s judgment and local guidelines. §When adverse events of neutropenia and leukopenia occurred, they were treated as deemed appropriate by the investigator according to local guidelines. The use of G-CSF was not recommended for primary prevention treatment, but if patients developed febrile neutropenia, the study was to be stopped, and the study drug suspended and appropriate drugs including G-CSF were to be given according to the local hospital guidelines.
Back to article page